Linked Life Data

11891480

Source:http://linkedlifedata.com/resource/pubmed/id/11891480

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11891480rdf:typepubmed:Citationlld:pubmed
pubmed-article:11891480lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:11891480lifeskim:mentionsumls-concept:C0011923lld:lifeskim
pubmed-article:11891480lifeskim:mentionsumls-concept:C0278678lld:lifeskim
pubmed-article:11891480lifeskim:mentionsumls-concept:C0003250lld:lifeskim
pubmed-article:11891480lifeskim:mentionsumls-concept:C1579762lld:lifeskim
pubmed-article:11891480lifeskim:mentionsumls-concept:C0032743lld:lifeskim
pubmed-article:11891480lifeskim:mentionsumls-concept:C0085264lld:lifeskim
pubmed-article:11891480lifeskim:mentionsumls-concept:C0009491lld:lifeskim
pubmed-article:11891480pubmed:issue3lld:pubmed
pubmed-article:11891480pubmed:dateCreated2002-3-13lld:pubmed
pubmed-article:11891480pubmed:abstractTextThe aims of this study were to establish the percentage of metastatic renal cell carcinoma (RCC) lesions detected by radioimmunoscintigraphy (RIS) with the chimeric monoclonal antibody 131I-cG250 versus positron emission tomography (PET) with 18F-labelled deoxyglucose ([18F]FDG), and to evaluate the use of these radionuclide imaging modalities compared with routinely used imaging techniques. Twenty patients with metastatic RCC disease were examined with [18F]FDG-PET and 131I-cG250 RIS within 1 week. Total body gamma camera images were obtained up to 120h after injection of 232MBq 131I-cG250. Total body PET scanning was performed 45-60 min after intravenous injection of 370MBq [18F]FDG. Nuclear medicine techniques were compared to routine imaging procedures. Routine imaging modalities revealed a total of 79 metastases. [18F]FDG-PET and 131I-cG250 RIS detected 33 previously unknown metastases, of which 32 were [18F]FDG positive and seven were 131I-cG250 positive. Of the 112 tumour lesions that were documented, [18F]FDG-PET detected 69% (77 out of 112), whereas 131I-cG250 RIS detected only 30% (34 out of 112). In conclusion, [18F]FDG-PET is superior to 131I-cG250 RIS in detecting metastases in patients with metastatic RCC, and therefore seems a promising tool for (re)staging patients with RCC. The usefulness of RIS with a diagnostic dose of 131I-cG250 seems to be restricted to selecting patients for radioimmunotherapy with 131I-cG250.lld:pubmed
pubmed-article:11891480pubmed:languageenglld:pubmed
pubmed-article:11891480pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11891480pubmed:citationSubsetIMlld:pubmed
pubmed-article:11891480pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11891480pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11891480pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11891480pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11891480pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11891480pubmed:statusMEDLINElld:pubmed
pubmed-article:11891480pubmed:monthMarlld:pubmed
pubmed-article:11891480pubmed:issn0143-3636lld:pubmed
pubmed-article:11891480pubmed:authorpubmed-author:LaneMMlld:pubmed
pubmed-article:11891480pubmed:authorpubmed-author:DoryLLlld:pubmed
pubmed-article:11891480pubmed:authorpubmed-author:MergenthalerH...lld:pubmed
pubmed-article:11891480pubmed:authorpubmed-author:BoermanO COClld:pubmed
pubmed-article:11891480pubmed:authorpubmed-author:BihlHHlld:pubmed
pubmed-article:11891480pubmed:authorpubmed-author:OosterwijkEElld:pubmed
pubmed-article:11891480pubmed:authorpubmed-author:SteffensM GMGlld:pubmed
pubmed-article:11891480pubmed:authorpubmed-author:BrouwersA HAHlld:pubmed
pubmed-article:11891480pubmed:authorpubmed-author:CorstensF H...lld:pubmed
pubmed-article:11891480pubmed:authorpubmed-author:OyenW J GWJlld:pubmed
pubmed-article:11891480pubmed:issnTypePrintlld:pubmed
pubmed-article:11891480pubmed:volume23lld:pubmed
pubmed-article:11891480pubmed:ownerNLMlld:pubmed
pubmed-article:11891480pubmed:authorsCompleteYlld:pubmed
pubmed-article:11891480pubmed:pagination229-36lld:pubmed
pubmed-article:11891480pubmed:dateRevised2011-7-29lld:pubmed
pubmed-article:11891480pubmed:meshHeadingpubmed-meshheading:11891480...lld:pubmed
pubmed-article:11891480pubmed:meshHeadingpubmed-meshheading:11891480...lld:pubmed
pubmed-article:11891480pubmed:meshHeadingpubmed-meshheading:11891480...lld:pubmed
pubmed-article:11891480pubmed:meshHeadingpubmed-meshheading:11891480...lld:pubmed
pubmed-article:11891480pubmed:meshHeadingpubmed-meshheading:11891480...lld:pubmed
pubmed-article:11891480pubmed:meshHeadingpubmed-meshheading:11891480...lld:pubmed
pubmed-article:11891480pubmed:meshHeadingpubmed-meshheading:11891480...lld:pubmed
pubmed-article:11891480pubmed:meshHeadingpubmed-meshheading:11891480...lld:pubmed
pubmed-article:11891480pubmed:meshHeadingpubmed-meshheading:11891480...lld:pubmed
pubmed-article:11891480pubmed:meshHeadingpubmed-meshheading:11891480...lld:pubmed
pubmed-article:11891480pubmed:meshHeadingpubmed-meshheading:11891480...lld:pubmed
pubmed-article:11891480pubmed:meshHeadingpubmed-meshheading:11891480...lld:pubmed
pubmed-article:11891480pubmed:year2002lld:pubmed
pubmed-article:11891480pubmed:articleTitle131 I-cG250 monoclonal antibody immunoscintigraphy versus [18 F]FDG-PET imaging in patients with metastatic renal cell carcinoma: a comparative study.lld:pubmed
pubmed-article:11891480pubmed:affiliationDepartment of Nuclear Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands. a.brouwers@nugen.azn.nllld:pubmed
pubmed-article:11891480pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11891480pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:11891480pubmed:publicationTypeComparative Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11891480lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11891480lld:pubmed